ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IDIX (MM)

24.50
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:IDIX NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.50 0.00 01:00:00

Idenix to Host Conference Call Discussing Third Quarter 2005 Financial Results on November 3, 2005 at 4:30 p.m. ET

28/10/2005 2:00pm

PR Newswire (US)


(MM) (NASDAQ:IDIX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more (MM) Charts.
CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (NASDAQ:IDIX) today announced that it will report its financial results for the third quarter of 2005 on Thursday, November 3, 2005, after the U.S. financial markets close. In conjunction with the issuance of the press release, management will host a conference call at 4:30 p.m. ET on Thursday, November 3, 2005, to discuss the company's financial results for the third quarter of 2005 and review financial guidance and milestones. To access the call please dial (800) 774-5358 US/Canada or (706) 643-0743 International and enter passcode 1725059 or to listen to a live webcast of the call, go to "Events" in the Idenix Investor Center at http://www.idenix.com/. An archived webcast will be available on the Idenix website for two weeks after the call. A replay of the call will also be available from 8:00 p.m. ET on November 3, 2005, until 8:00 p.m. ET on November 17, 2005. To access the replay, please dial 800-642-1687 or 706-645-9291 (international), and provide the passcode 1725059. Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus. Idenix's headquarters are located in Cambridge, Massachusetts and it has drug discovery operations in Montpellier, France and Cagliari, Italy. For more information on Idenix, please visit http://www.idenix.com/. Contact: Idenix Pharmaceuticals, Inc. Media: Teri Dahlman (617) 995-9905 Investors: Amy Sullivan (617) 995-9838 DATASOURCE: Idenix Pharmaceuticals, Inc. CONTACT: Media: Teri Dahlman, +1-617-995-9905; or Investors: Amy Sullivan, +1-617-995-9838, both of Idenix Pharmaceuticals, Inc. Web site: http://www.idenix.com/

Copyright

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock